Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,054 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sensitive Skin Clear all

Conditions: Skin Diseases
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atopic Dermatitis
Interventions: Text messages; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: Up to 6 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
Interventions: Placebo, Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous, MEDI4212 60 mg Subcutaneous, MEDI4212 150 mg Subcutaneous, MEDI4212 300 mg Subcutaneous, MEDI4212 300 mg Intravenous; Other · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 295 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Cypress, California • Glendale, California • Denver, Colorado + 4 more

Conditions: Hereditary Angioedema, HAE
Interventions: BCX4161, Placebo; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 25
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Granada Hills, California + 21 more

Conditions: Chronic Inducible Urticaria
Interventions: Remibrutinib, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 25
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 21 more

Conditions: Dermatitis Atopic
Interventions: dupilumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years to 14 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Denver, Colorado • St Louis, Missouri • New York, New York

Conditions: Mastocytosis
Interventions: Collection of blood and bone marrow; Other
Lead sponsor: University of Michigan; Other
Eligibility: Not listed
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Atopic Dermatitis, Plaque Psoriasis
Interventions: PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%, PF-07038124 ointment 0.06%; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 23
States / cities: Encinitas, California • Los Angeles, California • Cape Coral, Florida + 17 more

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 794 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 40
States / cities: Hot Springs, Arkansas • Encinitas, California • Fullerton, California + 35 more

Conditions: Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
Interventions: KT-474/Placebo, KT-474; Drug
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Phoenix, Arizona • Sun City West, Arizona • Boynton Beach, Florida + 8 more

Conditions: Atopic Dermatitis
Interventions: Dupilumab, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 64 Years
Enrollment: 920 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 58
States / cities: Phoenix, Arizona • Fayetteville, Arkansas • North Little Rock, Arkansas + 49 more

Conditions: Atopic Dermatitis, Eczema, Asthma, Food Allergies, Allergic Rhinitis
Interventions: Lipikar Balm AP; Drug
Lead sponsor: Cosmetique Active International; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Canton, Michigan • Fort Gratiot, Michigan

Conditions: Dermatitis, Atopic, Eczema
Interventions: Desonide Cream, Amino Acid Moisturizing Cream; Drug · Other
Lead sponsor: NeoStrata Company, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Vasculitis, Systemic Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis, Eosinophilic Granulomatosis, Temporal Arteritis, Wegener Granulomatosis, Henoch-Schoenlein Purpura, Microscopic Polyangiitis, Polyarteritis Nodosa (PAN), Takayasu's Arteritis, Urticarial Vasculitis
Interventions: online questionnaire; Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Atopic Dermatitis
Interventions: Dupilumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography; Device
Lead sponsor: U-Systems, Inc.; Industry
Eligibility: 25 Years and older · Female only
Enrollment: 15,679 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 11
States / cities: Indio, California • Monterey, California • Washington D.C., District of Columbia + 8 more

Conditions: Atopic Dermatitis, Atopic Disorders, Eczema, Atopic Eczema
Interventions: Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 1 Day to 63 Days
Enrollment: 1,260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 4
States / cities: Denver, Colorado • Durham, North Carolina • Portland, Oregon + 1 more

Conditions: Hereditary Angioedema (HAE)
Interventions: Deucrictibant, Placebo; Drug
Lead sponsor: Pharvaris Netherlands B.V.; Industry
Eligibility: 12 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Little Rock, Arkansas • San Diego, California • Santa Monica, California + 3 more

Conditions: Atopic Dermatitis, Pruritus
Interventions: B244, Vehicle; Biological
Lead sponsor: AOBiome LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 56
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 50 more

Conditions: Sensitivity, Contact
Interventions: ATx201, ATx201 Placebo Gel; Drug
Lead sponsor: UNION therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Non-atopic, Atopic, Healthy, Normal, Allergy
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hereditary Angioedema, HAE
Interventions: Dose 1 of BMN 331, Dose 2 of BMN 331, Dose 3 of BMN 331, Dose 4 of BMN 331, Dose 5 of BMN 331, Dose 6 of BMN 331, Dose 7 of BMN 331; Genetic
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 13
States / cities: Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 10 more

Conditions: Dermatitis, Atopic
Interventions: GSK1070806, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 6
States / cities: Fountain Valley, California • Pompano Beach, Florida • Fayetteville, Georgia + 3 more

Conditions: Atopic Dermatitis
Interventions: Tradipitant, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 28
States / cities: Encinitas, California • Encino, California • Lomita, California + 22 more

Search by objective public record fields.

Adaption of the Skin Sun Sensitivity Scale

Texting Atopic Dermatitis Patients to Optimize Learning and EASI Scores

A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis

Molecular Mechanisms and Diagnosis of Mastocytosis

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis

Skin Effects of a Topical Amino Acid Moisturizing Cream and Desonide in Atopic Dermatitis

Impact of Vasculitis on Employment and Income

Molecular Signatures of Cutaneous Dupilumab Response

A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.

A Community-based Assessment of Skin Care, Allergies, and Eczema

Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis

Sensitization Study of ATx201 in Healthy Volunteers

Normal Blood, Bone Marrow and Buccal Mucosa Protocol

A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema

Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.

Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis